Published in J Neurol on February 01, 2006
Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I). Eur J Health Econ (2013) 0.81
Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. J Neurol (2016) 0.76
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord (2016) 0.75
Spastic Paralysis of the Elbow and Forearm. Semin Plast Surg (2016) 0.75
Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology (2013) 2.99
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Botulinum toxin: clinical use. Parkinsonism Relat Disord (2006) 1.23
Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord (2007) 1.06
The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey. Int J Rehabil Res (2010) 1.05
Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord (2005) 1.05
A tribute to Wilhelm H. Erb. J Neurol (2006) 1.02
Utility of the WHO-Five Well-being Index as a screening tool for depression in Parkinson's disease. Mov Disord (2010) 1.00
Subjective experience and coping in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord (2002) 0.97
Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. J Neurol Sci (2003) 0.97
Burden of care in amyotrophic lateral sclerosis. Palliat Med (2003) 0.96
Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J Neural Transm (Vienna) (2010) 0.92
Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm. J Neural Transm (Vienna) (2011) 0.91
FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord (2005) 0.91
Disability status and quality of life in multiple sclerosis: non-linearity of the Expanded Disability Status Scale (EDSS). Health Qual Life Outcomes (2010) 0.88
On the role of biomedical knowledge in the acquisition of clinical knowledge. Med Educ (2013) 0.87
Effects of acute psychological stress on adhesion molecules, interleukins and sex hormones: implications for coronary heart disease. Psychopharmacology (Berl) (2002) 0.87
Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry. J Neural Transm (Vienna) (2014) 0.87
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol (2007) 0.87
Classification of neurovascular compression in typical hemifacial spasm: three-dimensional visualization of the facial and the vestibulocochlear nerves. J Neurosurg (2007) 0.86
Yawning despite trismus in a patient with locked-in syndrome caused by a thrombosed megadolichobasilar artery. Clin Neurol Neurosurg (2003) 0.85
Classification of posture in poststroke upper limb spasticity: a potential decision tool for botulinum toxin A treatment? Int J Rehabil Res (2012) 0.85
Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes (2010) 0.84
Activation of the RAGE pathway: a general mechanism in the pathogenesis of polyneuropathies? Neurol Res (2007) 0.84
Is levodopa toxic? J Neurol (2004) 0.84
Intravascular lymphomatosis mimicking disseminated encephalomyelitis and encephalomyelopathy. Clin Neurol Neurosurg (2006) 0.83
Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia--report of 19 cases. Mov Disord (2008) 0.83
Botulinum toxin type B blocks sudomotor function effectively: a 6 month follow up. J Invest Dermatol (2003) 0.83
Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson's Disease. Open Neurol J (2007) 0.82
Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate. Eur Neurol (2003) 0.81
Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations. Auton Neurosci (2005) 0.80
Pramipexole extended release: a novel treatment option in Parkinson's disease. Parkinsons Dis (2010) 0.80
Fatigue and sleep-disordered breathing in multiple sclerosis: a clinically relevant association? Mult Scler Int (2013) 0.79
Duloxetine in the treatment of stress urinary incontinence. Ther Clin Risk Manag (2005) 0.79
Discussing living wills. A qualitative study of a German sample of neurologists and ALS patients. J Neurol Sci (2005) 0.79
Antrochoanal polyp and obstructive sleep apnoea in children. J Laryngol Otol (2004) 0.79
Hashimoto's encephalopathy and motor neuron disease: a common autoimmune pathogenesis? Neurol India (2006) 0.78
Acute stroke and cytomegalovirus encephalitis: a coincidence? Ther Adv Neurol Disord (2010) 0.76
Early diagnosis of Parkinson's disease. J Neurol (2006) 0.76
Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study. Patient Prefer Adherence (2010) 0.75
Electrophysiologic testing of pelvic floor: some remarks. Dis Colon Rectum (2002) 0.75
Reduced body mass index in Parkinson's disease: contribution of comorbid depression. J Nerv Ment Dis (2013) 0.75
[Chronic cough in muscular dystrophy]. Med Klin (Munich) (2002) 0.75
Agglomeration and filtration of colloidal suspensions with DVLO interactions in simulation and experiment. J Colloid Interface Sci (2010) 0.75
[Ever more indications for botulinum toxin. A toxin for many cases (interview by Dr. Judith Neumaier)]. MMW Fortschr Med (2010) 0.75
Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data. J Med Econ (2014) 0.75
Do patients with motor neuron disease suffer from disorders of taste or smell? Amyotroph Lateral Scler (2011) 0.75
Successful treatment of methicillin-resistant Staphylococcus aureus meningitis using linezolid without removal of intrathecal infusion pump. Case report. J Neurosurg (2007) 0.75
Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights. Eur Neurol (2014) 0.75
Poster 361 Impact of Early Intervention with OnabotulinumtoxinA Treatment in Adult Patients with Post-Stroke Lower Limb Spasticity. PM R (2016) 0.75
Adult Spasticity International Registry Study: methodology and baseline patient, health care provider, and caregiver characteristics. J Rehabil Med (2017) 0.75
Successful treatment of axillary hyperhidrosis with very low doses of botulinum toxin B: a pilot study. Arch Dermatol Res (2003) 0.75
Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies. Ann Neurol (2002) 0.75
Botulinum toxin A in anal fissure: why does it work? Dis Colon Rectum (2004) 0.75
[Recommendations for home and long-term ventilation]. Med Klin (Munich) (2006) 0.75
Biopsy findings of symptomatic cerebral X-linked adrenoleucodystrophy and histological differentiation from multiple sclerosis. Neuropathol Appl Neurobiol (2014) 0.75